Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de fase 3 para avaliar a segurança e a eficácia do efgartigimod PH20 subcutâneo em pacientes adultos com trombocitopenia imune primária (ADVANCE SC+)

15 de outubro de 2026 atualizado por: argenx

Um estudo de fase 3, multicêntrico, aberto e de longo prazo para avaliar a segurança e a eficácia do efgartigimod (ARGX-113) PH20 subcutâneo em pacientes adultos com trombocitopenia imune primária

The main aim of the study is to evaluate the safety and efficacy of efgartigimod PH20 SC (subcutaneous) in adult patients with primary immune thrombocytopenia (ITP). Participants who completed the 24-week trial period of the ARGX- 113-2004 trial are given the opportunity to enter into this open-label extension trial and receive efgartigimod PH20 SC.

Participants will be offered the opportunity to continue in this trial if they have completed the first 52-week treatment period unless efgartigimod becomes commercially available for patients with primary ITP or becomes available through another program for patients with primary ITP, whichever comes first. A maximum of three additional 52-week treatment periods will be offered to the participant to continue this trial.

The total trial duration per participant is up to 4 years (52-week treatment period, extendable with three additional 52-week treatment periods) + 8 weeks follow-up period.

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

173

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Buenos Aires, Argentina
        • Investigator Site 0540001
      • Buenos Aires, Argentina
        • Investigator site 540004
      • Garran, Austrália
        • Investigator Site 0610012
      • West Perth, Austrália
        • Investigator Site 0610003
      • Westmead, Austrália
        • Investigator site 610005
      • Plovdiv, Bulgária
        • Investigator Site 3590017
      • Reñaca, Chile
        • Investigator site 0560003
      • Santiago, Chile
        • Investigator site 560002
      • Temuco, Chile
        • Investigator site 0560004
      • Beijing, China
        • Investigator site 860013
      • Bengbu, China
        • Investigator Site 0860008
      • Huizhou, China
        • Investigator site 860055
      • Shenzhen, China
        • Investigator Site 0860015
      • Tianjin, China
        • Investigator Site 0860001
      • Wuhan, China
        • Investigator Site 0860010
      • Wuxi, China
        • Investigator Site 0860002
      • Zhengzhou, China
        • Investigator Site 0860011
      • Zhenjiang, China
        • Investigator site 860058
      • Seoul, Coréia do Sul
        • Investigator site 820004
      • Seoul, Coréia do Sul
        • Investigator site KO0820007
    • Arkansas
      • Bentonville, Arkansas, Estados Unidos, 72758
        • Investigator Site 0010116
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20007
        • Investigator site 0010045
    • Indiana
      • Fort Wayne, Indiana, Estados Unidos, 46804
        • Investigator Site 0010062
    • Iowa
      • Iowa City, Iowa, Estados Unidos, 52242
        • Investigator site US0010042
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73142
        • Investigator Site 0010095
      • Tbilisi, Geórgia
        • Investigator site 9950009
      • Tbilisi, Geórgia
        • Investigator site 9950011
      • Tbilisi, Geórgia
        • Investigator Site 9950007
      • Athens, Grécia
        • Investigator site 300008
      • Thessaloniki, Grécia
        • Investigator Site 0300009
      • Dublin, Irlanda
        • Investigator site 3530003
      • Ferrara, Itália
        • Investigator site 390043
      • Milan, Itália
        • Investigator Site 0390032
      • Naples, Itália
        • Investigator Site 0390044
      • Naples, Itália
        • Investigator site 390041
      • Hirakata, Japão, 5731191
        • Investigator site JP0810015
      • Iruma, Japão
        • Investigator Site 0810017
      • Kanagawa, Japão
        • Investigator Site 0810053
      • Kitakyushu, Japão
        • Investigator Site 0810051
      • Shibukawa, Japão, 377-0280
        • Investigator site 0810016
      • Shimotsuke, Japão
        • Investigator site 810023
      • Tama, Japão
        • Investigator Site 0810038
      • Irbid, Jordânia
        • Investigator site 9620001
      • Aguascalientes, México
        • Investigator site 520002
      • Sarpsborg, Noruega, 1714
        • Investigator site 0470003
      • Christchurch, Nova Zelândia
        • Investigator site 640005
      • Katowice, Polônia, 40-519
        • Investigator site PL0480013
      • Nowy Sącz, Polônia
        • Investigator Site 0480026
      • Skorzewo, Polônia
        • Investigator Site 0480037
      • Lisbon, Portugal
        • Investigator Site 3510007
      • Porto, Portugal
        • Investigator site 3510004
      • Vila Nova de Gaia, Portugal
        • Investigator site 3510001
      • Coventry, Reino Unido
        • Investigator site 440005
      • London, Reino Unido
        • Investigator site UK044041
      • Penzance, Reino Unido, TR18 2PF
        • Investigator site UK0440014
      • Bucharest, Romênia
        • Investigator Site 0400005
      • Bucharest, Romênia
        • Investigator site 400012
      • Craiova, Romênia
        • Investigator Site 0400007
      • Kirov, Rússia
        • Investigator site 0070040
      • Moscow, Rússia
        • Investigator Site 0070026
      • Nizhny Novgorod, Rússia
        • Investigator Site 0070038
      • Novosibirsk, Rússia
        • Investigator Site 0070037
      • Bangkok, Tailândia
        • Investigator Site 0660002
      • Bangkok, Tailândia
        • Investigator Site 0660003
      • Bangkok, Tailândia
        • Investigator site 660005
      • Bangkok Noi, Tailândia
        • Investigator Site 0660001
      • Chiang Mai, Tailândia, 50200
        • Investigator site 0660004
      • Khon Kaen, Tailândia
        • Investigator site TH0660009
      • Sousse, Tunísia
        • Investigator site 2610001
      • Tunis, Tunísia
        • Investigator site 2160002
      • Adapazarı, Turquia (Türkiye)
        • Investigator Site 0900007
      • Ankara, Turquia (Türkiye)
        • Investigator Site 0900003
      • Ankara, Turquia (Türkiye)
        • Investigator Site 0900015
      • Ankara, Turquia (Türkiye)
        • Investigator Site 0900008
      • Izmir, Turquia (Türkiye)
        • Investigator site 900004
      • Kocaeli, Turquia (Türkiye)
        • Investigator Site 0900014
      • Mersin, Turquia (Türkiye)
        • Investigator site 900010
      • Tekirdağ, Turquia (Türkiye), 59100
        • Investigator site 0900017
      • Trabzon, Turquia (Türkiye)
        • Investigator site 900019
      • Johannesburg, África do Sul
        • Investigator site 270003
      • Observatory, África do Sul
        • Investigator site 270004
      • Pretoria, África do Sul
        • Investigator site 270001
      • Randburg, África do Sul
        • Investigator site 270002

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Ability to understand the requirements of the trial and provide written informed consent (including consent for the use and disclosure of research-related health information), willing and able to comply with the trial protocol procedures (including attending the required trial visits).
  • Participants enrolled in the ARGX-113-2004 trial who completed the 24-week trial period.
  • Agree to use contraceptives consistent with local regulations.
  • In addition to the above criteria, for participants who want to continue receiving efgartigimod during an additional 52-week treatment period, the participant has completed a 52-week treatment period.

Exclusion criteria:

  • Introduction or continuation of nonpermitted medications during the ARGX-113-2004 trial (such as anti-CD20 therapy, romiplostim, monoclonal antibodies, Fc fusion proteins, or live/live-attenuated vaccines).
  • Use of any other investigational drug or participation in any other investigational trial.
  • Known hypersensitivity reaction to efgartigimod PH20 SC or any of its excipients.
  • Pregnant or lactating females and those who intend to become pregnant during the trial or within 90 days after last dose of efgartigimod PH20 SC.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: efgartigimod PH20 SC

Patients receiving efgartigimod PH20 SC treatment

Subcutaneous injection with efgartigimod PH20 SC

Outros nomes:
  • ARGX-113 PH20 SC

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence of AEs, AESIs, SAEs
Prazo: Up to 216 weeks

AE : adverse event ; SAE : Serious adverse event ; AESI : adverse event of special interest.

Up to 216 weeks
Vital sign measurement: blood pressure in the overall population
Prazo: Up to 216 weeks
Up to 216 weeks
ECG: PR, QT and QRS interval in the overall population
Prazo: Up to 216 weeks
Up to 216 weeks
Laboratory safety evaluations: CRP analysis in the overall population
Prazo: Up to 216 weeks
Up to 216 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Extent of disease control defined as the percentage of weeks in the trial with platelet counts of ≥50×10E9/L
Prazo: Up to 52 weeks
Up to 52 weeks
Proportion of participants with overall platelet count response defined as achieving a platelet count of ≥50×10E9/L on at least 4 occasions at any time during the 52-week treatment period
Prazo: Up to 52 weeks
Up to 52 weeks
Mean change from baseline in platelet count at each visit
Prazo: Up to 52 weeks
Up to 52 weeks
For participants rolling over from the ARGX-113-2004 trial with a platelet count of <30×10E9/L: time to response defined as the time to achieve 2 consecutive platelet counts of ≥50×10E9/L
Prazo: Up to 52 weeks
Up to 52 weeks
The percentage of weeks in the trial with platelet counts of ≥30×10E9/L and ≥20×10E9/L above baseline
Prazo: Up to 52 weeks
Up to 52 weeks
In patients with a baseline platelet count of <15×10E9/L in the current trial (ARGX-113-2005), the percentage of weeks in the trial with platelet counts of ≥30×10E9/L and ≥20×10E9/L above baseline
Prazo: Up to 52 weeks
Up to 52 weeks
In participants with the first exposure to efgartigimod PH20 SC, the proportion of patients who achieve a sustained platelet response defined as achieving platelet counts of ≥50×10E9/L for at least 4 of the 6 visits between week 19 and week 24
Prazo: 5 weeks (from week 19 to week 24)
5 weeks (from week 19 to week 24)
In participants with the first exposure to efgartigimod PH20 SC, the proportion of patients achieving platelet counts of ≥50×10E9/L for at least 6 of the 8 visits between week 17 and week 24
Prazo: 7 weeks (from week 17 to week 24)
7 weeks (from week 17 to week 24)
Proportion of participants for whom dose and/or frequency of concurrent ITP therapies have been reduced compared to baseline
Prazo: Up to 52 weeks
Up to 52 weeks
Rate of receipt of rescue therapy (rescue per participant per month)
Prazo: Up to 52 weeks
Up to 52 weeks
Incidence of the WHO-classified bleeding events
Prazo: Up to 52 weeks

WHO : World Health Organization

Up to 52 weeks
Serum efgartigimod concentration observed predose (Ctrough)
Prazo: Up to 52 weeks
Up to 52 weeks
Change from baseline in FACIT-fatigue at planned visits
Prazo: Up to 52 weeks

The Functional Assessment of Chronic Illness Therapy Fatigue (FACIT- fatigue) scale is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured by recording item responses on a 4-point Likert scale ranging from 0 "not at all" to 4 "very much."

Up to 52 weeks
Change from baseline in FACT-Th6 at planned visits
Prazo: Up to 52 weeks

The Functional Assessment of Cancer Therapy questionnaire-Th6 (FACT-Th6) uses the Likert scale, with participants rating their degree of concern in the past 7 days. The 6 selected items pertain to ability to do usual activities, worry about problems with bleeding or bruising, worry about the possibility of serious bleeding, avoidance of physical or social activity because of concern with bleeding or bruising and frustration due to the inability to carry out usual activities.

Up to 52 weeks
Change from baseline in SF-36 at planned visits
Prazo: Up to 52 weeks

The SF-36 is a 36-item scale constructed to survey health-related QoL on 8 domains: limitations in physical activities due to health problems; limitations in social activities due to physical or emotional problems; limitations in usual role activities due to physical health problems; bodily pain; general mental health (psychological distress and well being); limitations in usual role activities due to emotional problems; vitality (energy and fatigue); and general health perceptions.

Up to 52 weeks
Change from baseline in ITP-PAQ at planned visits
Prazo: Up to 52 weeks

The ITP-Patient Assessment Questionnaire (ITP-PAQ) is a 44-item questionnaire to assess the health-related QoL in adults with ITP. It includes scales for physical health (symptoms, fatigue/sleep, bother, and activity), emotional health (psychological and fear), overall QoL, social activity, women's reproductive health, and work.

Up to 52 weeks
Pharmacodynamics markers: total IgG
Prazo: Up to 52 weeks
Up to 52 weeks
Percentage of participants who performed self-administration at home over time
Prazo: Up to 52 weeks
Up to 52 weeks
Percentage of caregivers who administered the injection to the patient at home over time
Prazo: Up to 52 weeks
Up to 52 weeks
Number of training visits needed for the participant or caregiver to be competent to start administering efgartigimod PH20 SC
Prazo: Up to 52 weeks
Up to 52 weeks
Percentage of self- or caregiver-supported administrations at home
Prazo: Up to 52 weeks
Up to 52 weeks
Incidence of antibodies to efgartigimod
Prazo: Up to 216 weeks
Up to 216 weeks
Titers of antibodies to efgartigimod
Prazo: Up to 216 weeks
Up to 216 weeks
Presence of NAb against efgartigimod
Prazo: Up to 216 weeks

NAb : Neutralizing antibodies

Up to 216 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

17 de novembro de 2021

Conclusão Primária (Estimado)

1 de outubro de 2027

Conclusão do estudo (Estimado)

1 de outubro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

15 de março de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

19 de março de 2021

Primeira postagem (Real)

24 de março de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de outubro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • ARGX-113-2005
  • 2024-513147-90-00 (Ctis)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .